594 related articles for article (PubMed ID: 18775650)
1. Molecular characterisation of cyp51A and cyp51B genes coding for P450 14alpha-lanosterol demethylases A (CYP51Ap) and B (CYP51Bp) from voriconazole-resistant laboratory isolates of Aspergillus flavus.
Krishnan-Natesan S; Chandrasekar PH; Alangaden GJ; Manavathu EK
Int J Antimicrob Agents; 2008 Dec; 32(6):519-24. PubMed ID: 18775650
[TBL] [Abstract][Full Text] [Related]
2. In vitro efficacy of the combination of voriconazole and anidulafungin against voriconazole-resistant cyp51A mutants of Aspergillus fumigatus.
Krishnan-Natesan S; Wu W; Chandrasekar PH
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):135-7. PubMed ID: 22608136
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the cyp51A gene and susceptibility to itraconazole in Aspergillus fumigatus serially isolated from a patient with lung aspergilloma.
Chen J; Li H; Li R; Bu D; Wan Z
J Antimicrob Chemother; 2005 Jan; 55(1):31-7. PubMed ID: 15563516
[TBL] [Abstract][Full Text] [Related]
4. Three-dimensional models of 14α-sterol demethylase (Cyp51A) from Aspergillus lentulus and Aspergillus fumigatus: an insight into differences in voriconazole interaction.
Alcazar-Fuoli L; Cuesta I; Rodriguez-Tudela JL; Cuenca-Estrella M; Sanglard D; Mellado E
Int J Antimicrob Agents; 2011 Nov; 38(5):426-34. PubMed ID: 21871783
[TBL] [Abstract][Full Text] [Related]
5. Isolation of multiple-triazole-resistant Aspergillus fumigatus strains carrying the TR/L98H mutations in the cyp51A gene in India.
Chowdhary A; Kathuria S; Randhawa HS; Gaur SN; Klaassen CH; Meis JF
J Antimicrob Chemother; 2012 Feb; 67(2):362-6. PubMed ID: 22028200
[TBL] [Abstract][Full Text] [Related]
6. Azole antifungal resistance in Aspergillus fumigatus: 2008 and 2009.
Bueid A; Howard SJ; Moore CB; Richardson MD; Harrison E; Bowyer P; Denning DW
J Antimicrob Chemother; 2010 Oct; 65(10):2116-8. PubMed ID: 20729241
[TBL] [Abstract][Full Text] [Related]
7. Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs.
Mellado E; Garcia-Effron G; Alcazar-Fuoli L; Cuenca-Estrella M; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2004 Jul; 48(7):2747-50. PubMed ID: 15215142
[TBL] [Abstract][Full Text] [Related]
8. Targeted gene disruption of the 14-alpha sterol demethylase (cyp51A) in Aspergillus fumigatus and its role in azole drug susceptibility.
Mellado E; Garcia-Effron G; Buitrago MJ; Alcazar-Fuoli L; Cuenca-Estrella M; Rodriguez-Tudela JL
Antimicrob Agents Chemother; 2005 Jun; 49(6):2536-8. PubMed ID: 15917566
[TBL] [Abstract][Full Text] [Related]
9. In vitro susceptibilities of Aspergillus spp. causing otomycosis to amphotericin B, voriconazole and itraconazole.
Kaya AD; Kiraz N
Mycoses; 2007 Nov; 50(6):447-50. PubMed ID: 17944704
[TBL] [Abstract][Full Text] [Related]
10. Molecular Identification, Antifungal Susceptibility Testing, and Mechanisms of Azole Resistance in
Rivero-Menendez O; Soto-Debran JC; Medina N; Lucio J; Mellado E; Alastruey-Izquierdo A
Antimicrob Agents Chemother; 2019 Sep; 63(9):. PubMed ID: 31285229
[TBL] [Abstract][Full Text] [Related]
11. Differential expression of ATP-binding cassette and/or major facilitator superfamily class efflux pumps contributes to voriconazole resistance in Aspergillus flavus.
Natesan SK; Lamichchane AK; Swaminathan S; Wu W
Diagn Microbiol Infect Dis; 2013 Aug; 76(4):458-63. PubMed ID: 23886435
[TBL] [Abstract][Full Text] [Related]
12. In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.
Shivaprakash MR; Geertsen E; Chakrabarti A; Mouton JW; Meis JF
Mycoses; 2011 Sep; 54(5):e583-9. PubMed ID: 21518026
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.
Buil JB; Rijs AJMM; Meis JF; Birch M; Law D; Melchers WJG; Verweij PE
J Antimicrob Chemother; 2017 Sep; 72(9):2548-2552. PubMed ID: 28605488
[TBL] [Abstract][Full Text] [Related]
14. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles.
van der Linden JW; Camps SM; Kampinga GA; Arends JP; Debets-Ossenkopp YJ; Haas PJ; Rijnders BJ; Kuijper EJ; van Tiel FH; Varga J; Karawajczyk A; Zoll J; Melchers WJ; Verweij PE
Clin Infect Dis; 2013 Aug; 57(4):513-20. PubMed ID: 23667263
[TBL] [Abstract][Full Text] [Related]
15. Magnitude of Voriconazole Resistance in Clinical and Environmental Isolates of Aspergillus flavus and Investigation into the Role of Multidrug Efflux Pumps.
Paul RA; Rudramurthy SM; Dhaliwal M; Singh P; Ghosh AK; Kaur H; Varma S; Agarwal R; Chakrabarti A
Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126956
[TBL] [Abstract][Full Text] [Related]
16. Voriconazole resistance genes in Aspergillus flavus clinical isolates.
Zaini F; Lotfali E; Fattahi A; Siddig E; Farahyar S; Kouhsari E; Saffari M
J Mycol Med; 2020 Jun; 30(2):100953. PubMed ID: 32362445
[TBL] [Abstract][Full Text] [Related]
17. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B.
Paterson PJ; Seaton S; Prentice HG; Kibbler CC
J Antimicrob Chemother; 2003 Nov; 52(5):873-6. PubMed ID: 14519673
[TBL] [Abstract][Full Text] [Related]
18. SREBP-dependent triazole susceptibility in Aspergillus fumigatus is mediated through direct transcriptional regulation of erg11A (cyp51A).
Blosser SJ; Cramer RA
Antimicrob Agents Chemother; 2012 Jan; 56(1):248-57. PubMed ID: 22006005
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of azole resistance in Aspergillus fumigatus isolates from high-risk patients.
Fuhren J; Voskuil WS; Boel CH; Haas PJ; Hagen F; Meis JF; Kusters JG
J Antimicrob Chemother; 2015 Oct; 70(10):2894-8. PubMed ID: 26163402
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamics of anidulafungin against clinical Aspergillus fumigatus isolates in a nonneutropenic murine model of disseminated aspergillosis.
Seyedmousavi S; Brüggemann RJ; Melchers WJ; Verweij PE; Mouton JW
Antimicrob Agents Chemother; 2013 Jan; 57(1):303-8. PubMed ID: 23114773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
